血管扩张性休克中较高与较低血压目标的死亡效应:更新的系统评价与荟萃分析
本更新系统评价与荟萃分析按PRISMA指南进行、方案在PROSPERO预注册(CRD420251087844),检索PubMed、Embase、CENTRAL与Scopus自建库至2025年7月,纳入4项RCT共3873例成人血管扩张性休克患者,比较较高MAP目标(通常80±5 mmHg)与较低MAP目标(一般65±5 mmHg)。主要终点全因死亡:较高目标组28天死亡风险增加10%(RR 1.10,95%CI 1.01-1.19;P=0.03),90天死亡呈相似趋势(RR 1.10,95%CI 1.00-1.22;P=0.05)。较高目标还与无RRT天数减少(均数差-1.64,95%CI -3.05至-0.23;P=0.02)和心律失常风险增加(RR 1.32,95%CI 1.01-1.72;P=0.04)相关。贝叶斯分析显示28天死亡有害后验概率97.8%、90天98.7%。作者结论认为不应普遍采用高MAP目标,应鼓励采用较低MAP目标并避免过度使用血管活性药,未来研究应关注个体化血压而非固定目标。
要点
- 血管扩张性休克成人:较高MAP目标(通常80±5 mmHg)与较低目标(一般65±5 mmHg)相比,28天死亡RR 1.10(95%CI 1.01-1.19;P=0.03)。
- 90天死亡呈相似趋势:RR 1.10(95%CI 1.00-1.22;P=0.05),置信区间上限触及无效线。
- 较高MAP目标组无RRT天数更少(均数差-1.64,95%CI -3.05至-0.23;P=0.02),心律失常风险更高(RR 1.32,95%CI 1.01-1.72;P=0.04)。
- 亚组分析未显示任何患者组(包括高龄或慢性高血压者)从较高目标获益。
- 贝叶斯分析支持有害:28天死亡有害后验概率97.8%,90天98.7%,作者据此鼓励采用较低MAP目标。
适用人群与场景
- 成人血管扩张性休克患者,纳入比较较高MAP目标(通常80±5 mmHg)与较低MAP目标(一般65±5 mmHg)的RCT人群。
- 亚组包括高龄患者与慢性高血压患者;原文未报告其他纳入或排除标准。
研究设计与关键结果
- 研究类型:按PRISMA指南实施的系统评价与荟萃分析,方案在PROSPERO预注册(CRD420251087844),检索PubMed、Embase、CENTRAL、Scopus自建库至2025年7月。
- 纳入4项RCT、共3873例成人血管扩张性休克患者,比较较高MAP目标(通常80±5 mmHg)与较低目标(一般65±5 mmHg),采用随机效应模型、亚组分析与贝叶斯方法。
- 主要终点:较高MAP目标组28天死亡风险增加10%(RR 1.10,95%CI 1.01-1.19;P=0.03)。
- 90天死亡:RR 1.10(95%CI 1.00-1.22;P=0.05);无RRT天数均数差-1.64(95%CI -3.05至-0.23;P=0.02);心律失常RR 1.32(95%CI 1.01-1.72;P=0.04)。
- 亚组分析未发现任何患者组(包括高龄或慢性高血压者)从较高目标获益;贝叶斯分析28天死亡有害后验概率97.8%、90天98.7%。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析;结论强度为中等确定性(moderate certainty)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为应鼓励采用较低MAP目标,并强调避免过度使用血管活性药带来的潜在危害。
- 作者认为未来研究应关注个体化血压而非固定目标;原文未给出具体MAP数值推荐或药物剂量方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the impact of higher versus lower mean arterial pressure (MAP) targets on mortality and other outcomes in patients with vasodilatory shock.
DESIGN: A systematic review and meta-analysis of randomised controlled trials (RCTs) following PRISMA guidelines with the protocol preregistered with PROSPERO (CRD420251087844).
DATA SOURCES: PubMed, Embase, CENTRAL, and Scopus from their inception until July 2025.
METHODS: This review included RCTs that compared a higher MAP target arm, typically 80±5 mmHg or the physiologically higher target arm within the trial, to a lower target arm (generally 65±5 mmHg) in adult patients with vasodilatory shock. The primary outcome was all-cause mortality. The analysis utilised random-effects models, subgroup analyses, and Bayesian methods.
RESULTS: Four RCTs with a total of 3,873 patients were included. A higher MAP target was associated with a 10% increase in 28-day mortality (RR 1.10, 95% CI 1.01-1.19; P=0.03). A similar trend toward increased 90-day mortality was observed, with a risk ratio of 1.10 (95% CI 1.00-1.22; P=0.05). Subgroup analyses revealed no benefit from higher targets for any patient group, including those with advanced age or chronic hypertension. A higher MAP target was also linked to fewer RRT-free days (mean difference -1.64, 95% CI -3.05 to -0.23; P = 0.02) and a greater risk of arrhythmia (RR 1.32, 95% CI 1.01-1.72; P=0.04). The Bayesian analysis corroborated these findings, revealing a high posterior probability of harm (97.8% for 28-day mortality and 98.7% for 90-day mortality).
CONCLUSIONS: In patients with vasodilatory shock, universal high MAP targets are associated with increased mortality compared with lower targets, with moderate certainty. These results should encourage the adoption of lower MAP targets and highlight the importance of avoiding the potential harm associated with excessive vasopressor use. Future research should focus on individualised blood pressure rather than fixed targets.
参考来源
- Mendes H, King J, Kumar N, et al. Mortality effect of higher versus lower blood pressure targets in vasodilatory shock: an updated systematic review and meta-analysis. Crit Care. 2025. PMID: 41276856. doi:10.1186/s13054-025-05769-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。